株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心筋線維症:パイプライン製品分析

Myocardial Fibrosis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 350076
出版日 ページ情報 英文 65 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.35円で換算しております。
Back to Top
心筋線維症:パイプライン製品分析 Myocardial Fibrosis - Pipeline Review, H2 2016
出版日: 2016年12月21日 ページ情報: 英文 65 Pages
概要

心筋線維症は、心臓線維芽細胞の不適切な増殖によって心臓弁の異常肥大が起こる疾患です。その症状には、胸の痛み、腹部の膨満感、吐き気、疲労感などがあります。

当レポートでは、世界における心筋線維症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

心筋線維症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

心筋線維症:企業で開発中の治療薬

心筋線維症:大学/機関で研究中の治療薬

心筋線維症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

心筋線維症:企業で開発中の製品

心筋線維症:大学/機関で研究中の製品

心筋線維症の治療薬開発に従事している企業

  • AstraZeneca Plc
  • BioLineRx, Ltd.
  • Digna Biotech, S.L.
  • Evotec AG
  • Galectin Therapeutics, Inc.
  • GTx, Inc.
  • MandalMed, Inc.
  • miRagen Therapeutics, Inc.
  • ProMetic Life Sciences Inc.
  • Virocan Therapeutics Private Limited

心筋線維症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

心筋線維症:最近のパイプライン動向

心筋線維症:休止中のプロジェクト

心筋線維症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8818IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2016, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 8 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myocardial Fibrosis Overview
  • Therapeutics Development
  • Pipeline Products for Myocardial Fibrosis - Overview
    • Pipeline Products for Myocardial Fibrosis - Comparative Analysis
    • Myocardial Fibrosis - Therapeutics under Development by Companies
    • Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Myocardial Fibrosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Myocardial Fibrosis - Products under Development by Companies
  • Myocardial Fibrosis - Products under Investigation by Universities/Institutes
  • Myocardial Fibrosis - Companies Involved in Therapeutics Development
    • Daewoong Pharmaceutical Co Ltd
    • Evotec AG
    • Galectin Therapeutics Inc
    • GTx Inc
    • Invivosciences Inc
    • Lead Discovery Center GmbH
    • MandalMed Inc
    • miRagen Therapeutics Inc
    • Regulus Therapeutics Inc
  • Myocardial Fibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Drugs for Tissue Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWN-10290 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GMCT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GTx-878 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGN-4220 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NM-922 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Soluble Epoxide Hydrolase for Myocardial Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-20102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPI-2049 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Myocardial Fibrosis - Dormant Projects
  • Myocardial Fibrosis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Myocardial Fibrosis, H2 2016
  • Number of Products under Development for Myocardial Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Myocardial Fibrosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016
  • Myocardial Fibrosis - Pipeline by Evotec AG, H2 2016
  • Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2016
  • Myocardial Fibrosis - Pipeline by GTx Inc, H2 2016
  • Myocardial Fibrosis - Pipeline by Invivosciences Inc, H2 2016
  • Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Myocardial Fibrosis - Pipeline by MandalMed Inc, H2 2016
  • Myocardial Fibrosis - Pipeline by miRagen Therapeutics Inc, H2 2016
  • Myocardial Fibrosis - Pipeline by Regulus Therapeutics Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Myocardial Fibrosis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Myocardial Fibrosis, H2 2016
  • Number of Products under Development for Myocardial Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top